Professur für Endokrinologie

Adresse:
Ulmenweg 18
91054 Erlangen


Publikationen (Download BibTeX)

Go to first page Go to previous page 1 von 2 Go to next page Go to last page

Yao, J., Garg, A., Chen, D., Capdevila, J., Engstrom, P., Pommier, R.,... Kulke, M.H. (2019). Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocrine-Related Cancer, 26(4), 391-403. https://dx.doi.org/10.1530/ERC-18-0332
Anthony, L., Kulke, M., Caplin, M., Bergsland, E., Oberg, K., Pavel, M.E.,... Jiang, W. (2019). Long-Term Follow Up of Patients With Carcinoid Syndrome Diarrhea Treated With Telotristat Ethyl: A Pooled Analysis of Phase 2 and 3 Trials. In PANCREAS (pp. 428-428). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Thürauf, N., Bachlechner, S., Denzer-Lippmann, M., Wielopolski, J., Fischer, M., Büttner, A.,... Kornhuber, J. (2019). Grehlin concentrations correlate with hunger and craving ratings following oral ingestion of macronutrients. In CHEMICAL SENSES (pp. E55-E56). OXFORD: OXFORD UNIV PRESS.
Lamarca, A., Ronot, M., Moall, S., Crona, J., Opalinska, M., Lopez, C.,... Dromain, C. (2019). Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study. In NEUROENDOCRINOLOGY (pp. 137-137). BASEL: KARGER.
Pavel, M.E., Dromain, C., Thanh, T.X.M., & Houchard, A. (2019). Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study. In NEUROENDOCRINOLOGY (pp. 157-157). BASEL: KARGER.
Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E.,... Singh, S. (2018). Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.
Pavel, M.E., Denecke, T., Lahner, H., Hoersch, D., Rinke, A., Koch, A.,... Raderer, M. (2018). Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study. (pp. 202-202).
Banz, S., Mellar, K., Letsch, A., Scheibenbogen, C., Pavel, M.E., & Grabowski, P. (2018). First Patient Survey about Tumor - Associated Fatigue in NEN. (pp. 59-59).
Dillon, J., Dillon, J., Kulke, M., Warner, R., Bergsland, E., Welin, S.,... Pavel, M.E. (2018). Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome. (pp. 224-224).
Chan, D.L., Yao, J.C., Carnaghi, C., Buzzoni, R., Herbst, F., Herbst, F.,... Singh, S. (2018). Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 151-151).
Lamarca, A., Crona, J., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2018). Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study. (pp. 178-178).
Mirakhur, B., Pavel, M.E., Pommier, R.F., Fisher, G.A., Phan, A.T., Massien, C.,... Vinik, A. (2018). BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS. Endocrine Practice, 24(11), 948-962. https://dx.doi.org/10.4158/EP-2018-0296
Fazio, N., Carnaghi, C., Buzzoni, R., Valle, J., Valle, J., Herbst, F.,... Yao, J.C. (2018). Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 211-211).
Crona, J., Crona, J., Lamarca, A., Ronot, M., Opalinska, M., Lopez Lopez, C.,... Dromain, C. (2018). Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study. (pp. 171-171).
Atanasov, G., Tsvetkova, ., Struecker, B., Andreou, A., Bahra, M., Prasad, .,... Pascher, A. (2018). Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors. (pp. 148-148).
Bachlechner, S., Denzer-Lippmann, M.Y., Wielopolski, J., Fischer, M., Büttner, A., Dörfler, A.,... Thürauf, N. (2017). The Effects of Different Isocaloric Oral Nutrient Solutions on Psychophysical, Metabolic, Cognitive, and Olfactory Function in Young Male Subjects. Frontiers in psychology, 8. https://dx.doi.org/10.3389/fpsyg.2017.01988
Denzer-Lippmann, M., Bachlechner, S., Wielopolski, J., Fischer, M., Büttner, A., Dörfler, A.,... Thürauf, N. (2017). The Effects of a Normal Rate versus a Slow Intervalled Rate of Oral Nutrient Intake and Intravenous Low Rate Macronutrient Application on Psychophysical Function - Two Pilot Studies. Frontiers in psychology, 8. https://dx.doi.org/10.3389/fpsyg.2017.01031
Reinauer, C., Bollow, E., Froehlich-Reiterer, E., Laubner, K., Bergis, D., Schöfl, C.,... Holl, R.W. (2017). Polycystic Ovary Syndrome (PCOS) in Juvenile and Adult Type 1 Diabetes in a German/Austrian Cohort. Experimental and Clinical Endocrinology & Diabetes, 125(10), 661-668. https://dx.doi.org/10.1055/s-0043-104701
Thürauf, N., Denzer-Lippmann, M., Bachlechner, S., Wielopolski, J., Fischer, M., Büttner, A.,... Kornhuber, J. (2017). Effects of different isocaloric oral nutrient solutions on olfactory functioning, hunger and food craving. (pp. E55-E55).
Hoersch, D., Raderer, M., Lahner, H., Rinke, A., Denecke, T., Koch, A.,... Pavel, M.E. (2017). Combined lanreotide autogel and temozolomide in progressive neuroendocrine tumours: an interim safety analysis of the SONNET study. (pp. 238-238).

Zuletzt aktualisiert 2017-10-05 um 02:00